Brickell Biotech Valuation
| BBIDelisted Stock | USD 1.79 0.34 23.45% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Brickell Biotech shows a prevailing Real Value of $1.46 per share. The current price of the firm is $1.79. Our model approximates the value of Brickell Biotech from analyzing the firm fundamentals such as Operating Margin of (6.58) %, return on equity of -1.57, and Shares Outstanding of 2.87 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Brickell Biotech's price fluctuation is very steady at this time. Calculation of the real value of Brickell Biotech is based on 3 months time horizon. Increasing Brickell Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Brickell Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Brickell Stock. However, Brickell Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.79 | Real 1.46 | Hype 1.79 | Naive 1.91 |
The intrinsic value of Brickell Biotech's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Brickell Biotech's stock price.
Estimating the potential upside or downside of Brickell Biotech helps investors to forecast how Brickell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Brickell Biotech more accurately as focusing exclusively on Brickell Biotech's fundamentals will not take into account other important factors: Brickell Biotech Total Value Analysis
Brickell Biotech is currently forecasted to have company total value of (8.35 M) with market capitalization of 6.75 M, debt of 69 K, and cash on hands of 17.29 M. The negative valuation of Brickell Biotech may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial commitments of the company both on and off balance sheet. Investors should carefully check all of the Brickell Biotech fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(8.35 M) | 6.75 M | 69 K | 17.29 M |
Brickell Biotech Investor Information
About 13.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.41. Some equities with similar Price to Book (P/B) outperform the market in the long run. Brickell Biotech recorded a loss per share of 0.42. The entity last dividend was issued on the 3rd of September 2019. The firm had 1:45 split on the 5th of July 2022. Brickell Biotech is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Brickell Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Brickell Biotech has an asset utilization ratio of 1.36 percent. This signifies that the Company is making $0.0136 for each dollar of assets. An increasing asset utilization means that Brickell Biotech is more efficient with each dollar of assets it utilizes for everyday operations.Brickell Biotech Ownership Allocation
Almost 85.73 percent of Brickell Biotech outstanding shares are held by general public with 1.2 (percent) owned by insiders and only 13.08 % by other corporate entities.Brickell Biotech Profitability Analysis
The company reported the last year's revenue of 404 K. Reported Net Loss for the year was (39.47 M) with loss before taxes, overhead, and interest of (27.83 M).About Brickell Biotech Valuation
An absolute valuation paradigm, as applied to Brickell Stock, attempts to find the value of Brickell Biotech based on its fundamental and basic technical indicators. By analyzing Brickell Biotech's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Brickell Biotech's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Brickell Biotech. We calculate exposure to Brickell Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Brickell Biotech's related companies.Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NCM Exchange. It employs 16 people.
Brickell Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.8 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Brickell Stock
If you are still planning to invest in Brickell Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Brickell Biotech's history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |